JP2010511631A5 - - Google Patents

Download PDF

Info

Publication number
JP2010511631A5
JP2010511631A5 JP2009539526A JP2009539526A JP2010511631A5 JP 2010511631 A5 JP2010511631 A5 JP 2010511631A5 JP 2009539526 A JP2009539526 A JP 2009539526A JP 2009539526 A JP2009539526 A JP 2009539526A JP 2010511631 A5 JP2010511631 A5 JP 2010511631A5
Authority
JP
Japan
Prior art keywords
oxo
methyl
hydrazino
ylidene
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009539526A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511631A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/086186 external-priority patent/WO2008070583A2/en
Publication of JP2010511631A publication Critical patent/JP2010511631A/ja
Publication of JP2010511631A5 publication Critical patent/JP2010511631A5/ja
Pending legal-status Critical Current

Links

JP2009539526A 2006-12-01 2007-11-30 トロンボポエチン擬態物 Pending JP2010511631A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86196306P 2006-12-01 2006-12-01
PCT/US2007/086186 WO2008070583A2 (en) 2006-12-01 2007-11-30 Thrombopoietin mimetics

Publications (2)

Publication Number Publication Date
JP2010511631A JP2010511631A (ja) 2010-04-15
JP2010511631A5 true JP2010511631A5 (enExample) 2011-01-27

Family

ID=39493014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009539526A Pending JP2010511631A (ja) 2006-12-01 2007-11-30 トロンボポエチン擬態物

Country Status (6)

Country Link
US (2) US7786159B2 (enExample)
EP (1) EP2086551A4 (enExample)
JP (1) JP2010511631A (enExample)
AU (1) AU2007329464A1 (enExample)
CA (1) CA2670345A1 (enExample)
WO (1) WO2008070583A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
AU2007329464A1 (en) 2006-12-01 2008-06-12 Stategics, Inc. Thrombopoietin mimetics
EP2427053A4 (en) * 2009-05-07 2012-12-05 Glaxosmithkline Llc METHOD FOR TREATING THROMBOCYTOPENIA
US8476249B2 (en) 2009-05-07 2013-07-02 Glaxosmithkline Llc Method of treating thrombocytopenia
CN101921232A (zh) * 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
WO2012121958A2 (en) * 2011-03-08 2012-09-13 Glaxosmithkline Llc Combination
WO2013072921A2 (en) * 2011-09-13 2013-05-23 Glenmark Generics Limited Process for preparation of substituted 3'-hydrazino-biphenyl-3-carboxylic acid compounds
CN109293551A (zh) 2011-11-14 2019-02-01 利亘制药公司 与粒细胞集落刺激因子受体相关的方法和组合物
JP6150374B2 (ja) * 2012-11-15 2017-06-21 国立大学法人弘前大学 放射線被ばく治療剤及び放射線被ばく治療方法
US9962370B2 (en) 2013-03-15 2018-05-08 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
CN104257928A (zh) * 2014-10-20 2015-01-07 王艳萍 一种治疗软组织损伤疼痛综合症的中药制剂
CA3070442A1 (en) 2017-07-26 2019-01-31 Janssen Pharmaceutica Nv Methods of protecting vascular integrity induced by targeted radiation therapy
WO2020154585A1 (en) * 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
WO2024249284A2 (en) * 2023-05-26 2024-12-05 Ipsen Pharma S.A.S. Bax activators and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3141772A (en) * 1963-08-09 1964-07-21 Polaroid Corp Photographic products, processes and compositions employing azo dye developers
BE621310A (enExample) * 1961-08-10
DE1182432B (de) * 1962-04-26 1964-11-26 Basf Ag Verfahren zur Herstellung von thermoplastischen farbigen makromolekularen Stoffen
US3666746A (en) * 1969-06-25 1972-05-30 Gaf Corp Pyrrolidonylphenyl azo dyestuffs
US5132189A (en) * 1989-09-07 1992-07-21 Fuji Electric Co., Ltd. Photoconductor for electrophotography
JPH04128767A (ja) * 1990-09-19 1992-04-30 Fuji Electric Co Ltd 電子写真用感光体
KR100423881B1 (ko) * 1999-07-29 2004-03-22 미쯔이카가쿠 가부시기가이샤 황색계 화합물을 이용한 잉크젯기록용 수계 잉크
ATE315934T1 (de) * 1999-09-10 2006-02-15 Smithkline Beecham Corp Thrombopoietin-mimetika
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
WO2003103686A1 (en) 2002-06-06 2003-12-18 Smithkline Beecham Corporation Thrombopoietin mimetics
WO2005118551A2 (en) 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
KR100958337B1 (ko) * 2004-10-25 2010-05-17 리간드 파마슈티칼스 인코포레이티드 트롬보포이에틴 활성 조절 화합물 및 방법
US7226575B2 (en) * 2004-11-30 2007-06-05 Chevron U.S.A. Inc. Boron-containing molecular sieve CHA
KR20080080305A (ko) * 2005-11-23 2008-09-03 리간드 파마슈티칼스 인코포레이티드 트롬보포이에틴 활성 조절 화합물 및 이의 조절 방법
MX2008008642A (es) 2006-01-13 2008-09-12 Pharmacyclics Inc Inhibidores de las tirosina cinasas y usos de los mismos.
AU2007329464A1 (en) * 2006-12-01 2008-06-12 Stategics, Inc. Thrombopoietin mimetics

Similar Documents

Publication Publication Date Title
JP2010511631A5 (enExample)
JP2012533546A5 (enExample)
JP2008201787A5 (enExample)
JP2012502037A5 (enExample)
JP2011524850A5 (enExample)
JP2011529054A5 (enExample)
JP2014515013A5 (enExample)
CO6612204A2 (es) Nuevas composiciones de 1-(2(2.4 dimetil-fenilsulfanil)- fenil) piperazina
JP2010077141A5 (enExample)
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
JP2007508360A5 (enExample)
JP2006514611A5 (enExample)
CN1878757A (zh) 吡啶酮衍生物及其应用
JP2009538276A5 (enExample)
JP2010526840A5 (enExample)
JP2010507641A5 (enExample)
JP2012507535A5 (enExample)
JP2006501306A5 (enExample)
JP2008546770A5 (enExample)
NO20082498L (no) Diarylurea for behandling av pulmonar hypertensjon
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
JP2008534558A5 (enExample)
JP2012501334A5 (enExample)
JP2010500284A5 (enExample)
WO2007057221A3 (en) Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases